TUCSON, AZ / ACCESSWIRE / January 18, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fund raise led by a $1.5M investment from JSR Life Sciences, LLC. The convertible note close brings the total Aqualung funding to date to >$17M, with $14 million derived from non-dilutive capital via NIH-funded grants and an earlier successfully executed $700,000 early seed round. In addition to investments in the convertible note, JSR Life Sciences has committed an additional $1.5M to the upcoming $10M Series A capital raise.Continue reading→

Clinical performance study published in Future Oncology reinforces the independent value of DecisionDx-SCC to inform risk-appropriate patient management decisionsContinue reading→

Dr. Lindsey Murray will lead C-Path’s New Rare Disease COA ConsortiumContinue reading→

The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseasesContinue reading→

DecisionDx-UMSeq identified somatic mutations relevant to uveal melanoma and is indicated as a complement to DecisionDx®-UM and DecisionDx®-PRAME, using the same biopsy tissueContinue reading→

Through collaboration and sponsorship with Perkins Coie LLP, UACI is offering a sponsored year at the incubator for one deserving startup with a committed team that is working to solve a significant business or social challenge. The winning team will also receive a cash award of $15,000, which includes funding for a legal project budget. The total prize package is valued at $25,000.

Continue reading→

TUCSON, Ariz., January 11, 2022 — Critical Path Institute (C-Path) is pleased to announce the Electronic Patient-Reported Outcome (ePRO) Consortium is now the Electronic Clinical Outcome Assessment (eCOA) Consortium. This rebranding more accurately reflects the expanded portfolio range of work performed by the consortium, the actual capabilities of member firms and the scope and significance of the consortium’s role. The new name was chosen to more authentically characterize the mission and aims of the consortium, which have evolved significantly since its inception in 2011.Continue reading→

Analysis of molecular-level biological changes could lead to better predictive models that would enhance assessment of suicide riskContinue reading→

The U.S. Department of Health and Human Services (HHS) Office on Women’s Health announced the 20 winners of Phase I of the HHS Hypertension Innovator Award Competition.  The competition was created to identify effective, pre-existing programs that care for people with hypertension where the programs could be or are already applied to women with hypertension who are pregnant and/or postpartum. The goal of the competition is to demonstrate sustainability and the ability to replicate and/or expand programs that provide effective monitoring and follow-up of hypertension for women who are pregnant and/or postpartum.

Congratulations go to Emagine Solutions Technology and Valleywise (in collaboration with Creighton University).Continue reading→

If understanding the inner workings of the brain is on your mind, now is the time to explore the Banner-ASU Neuroscience Scholars program. Top-achieving college undergraduate and graduate science students are eligible to apply for the paid eight-week training program. Applications must be received by March 1.Continue reading→